Cost of Revenue Trends: ADMA Biologics, Inc. vs Ligand Pharmaceuticals Incorporated

Biotech Cost Trends: ADMA vs. Ligand

__timestampADMA Biologics, Inc.Ligand Pharmaceuticals Incorporated
Wednesday, January 1, 201437423679136000
Thursday, January 1, 201543114615807000
Friday, January 1, 201663607615571000
Sunday, January 1, 2017291643215366000
Monday, January 1, 2018421946356337000
Tuesday, January 1, 20193950423811347000
Wednesday, January 1, 20206129142630419000
Friday, January 1, 20217976934162176000
Saturday, January 1, 202211881453552827000
Sunday, January 1, 202316927300035049000
Loading chart...

Unleashing insights

Cost of Revenue Trends: A Comparative Analysis

In the ever-evolving landscape of biotechnology and pharmaceuticals, understanding cost dynamics is crucial. Over the past decade, ADMA Biologics, Inc. and Ligand Pharmaceuticals Incorporated have showcased distinct trajectories in their cost of revenue. From 2014 to 2023, ADMA Biologics experienced a staggering increase of over 4,400%, peaking in 2023. This growth reflects their aggressive expansion and scaling efforts. In contrast, Ligand Pharmaceuticals saw a more modest increase of approximately 280% during the same period, indicating a more stable cost structure.

Key Insights

  • ADMA Biologics: Notable spikes in 2017 and 2023 suggest strategic investments or expansions.
  • Ligand Pharmaceuticals: Consistent yet moderate growth, with a significant rise in 2020, possibly due to market adaptations.
    These trends highlight the diverse strategies employed by these companies in navigating the competitive biotech sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025